Krishna Institute of Medical Sciences has received approval from the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for the listing of 19,867,549 equity shares issued through a Qualified Institutions Placement (QIP). The shares, issued at a price of ₹755 per share, were allotted to eligible qualified institutional buyers following the issue's closure on June 19, 2026. The allotment includes a premium of ₹753 per equity share and incorporates a discount of ₹16.73 per share, equivalent to 2.17% of the floor price of ₹771.73.

The listing approvals, granted on June 22, 2026, by the NSE and subsequently by the BSE, pertain to equity shares of ₹2 each bearing distinctive numbers from 400138936 to 420006484. Trading in these shares will commence only after the company files the necessary confirmation letters from the depositories, CDSL and NSDL, regarding the crediting of shares to the beneficiaries' accounts. The company had previously secured board approval on March 11, 2026, and shareholder consent via postal ballot on April 15, 2026.

Issue Details

The Finance & Investment Committee approved the closure of the issue period and finalized the allocation during a meeting held on June 19, 2026. The committee determined the issue price in consultation with the book running lead managers, applying the permitted discount on the floor price calculated under Regulation 176(1) of the SEBI ICDR Regulations. The trading window for designated persons, which was closed since the issue opening, will reopen 48 hours after the determination of the issue price.

krishna institute of medical sciences witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 7,09,779 shares changing hands in a single transaction. The trade was executed at ₹807.40 per share, aggregating to a total deal value of ₹57.31 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Block trades of this magnitude are typically executed by institutional investors or large market participants and are conducted outside the regular order book to minimise market impact. Such transactions are closely monitored by market participants as they may reflect significant portfolio activity in the stock.